Advertisement
Research Article| Volume 9, ISSUE 1, P137-152, March 1989

Apoprotein Measurements and Their Clinical Application

  • Author Footnotes
    * Research Professor of Medicine, and Adjunct Research Professor of Pathology, University of Washington; Associate Director, Northwest Lipid Research Center, Harbor-view Medical Center
    John J. Albers
    Correspondence
    Corresponding author: Northwest Lipid Research Center, 465 Harborview Hall, ZA-36, 326 9th Avenue, Seattle, Washington 98104.
    Footnotes
    * Research Professor of Medicine, and Adjunct Research Professor of Pathology, University of Washington; Associate Director, Northwest Lipid Research Center, Harbor-view Medical Center
    Affiliations
    From the Departments of Medicine and Pathology, University of Washington, Seattle, Washington
    Search for articles by this author
  • Author Footnotes
    † Professor of Medicine
    John D. Brunzell
    Footnotes
    † Professor of Medicine
    Affiliations
    From the Departments of Medicine and Pathology, University of Washington, Seattle, Washington
    Search for articles by this author
  • Author Footnotes
    ‡ Professor of Medicine, University of Washington; Director, Northwest Lipid Research Center, Harborview Medical Center
    Robert H. Knopp
    Footnotes
    ‡ Professor of Medicine, University of Washington; Director, Northwest Lipid Research Center, Harborview Medical Center
    Affiliations
    From the Departments of Medicine and Pathology, University of Washington, Seattle, Washington
    Search for articles by this author
  • Author Footnotes
    * Research Professor of Medicine, and Adjunct Research Professor of Pathology, University of Washington; Associate Director, Northwest Lipid Research Center, Harbor-view Medical Center
    † Professor of Medicine
    ‡ Professor of Medicine, University of Washington; Director, Northwest Lipid Research Center, Harborview Medical Center
DOI:https://doi.org/10.1016/S0272-2712(18)30646-2
Apoprotein Measurements and Their Clinical Application
Previous ArticleThe Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: An Approach to Accurate and Precise Lipid Measurements
Next ArticleThe Status of Hypertriglyceridemia as a Risk Factor for Coronary Heart Disease
      This paper is only available as a PDF. To read, Please Download here.
      A considerable body of epidemiological and clinical data suggests that apoprotein levels have promise as predictors of coronary disease risk and may offer information not available from blood lipid and lipoprotein levels. Assuming improvements in standardization and the availability of reference values, apoprotein measurements have wide applications in a variety of clinical settings.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. Adolphson JL, Albers JJ: Comparison of two commercial nephelometric methods for apoprotein A-I and apoprotein B with standardized apoprotein A-I and B radioimmunoassays. J Lipid Res, in press

        • Alaupovic P.
        • McConathy J.
        • Fesmire J.
        • et al.
        Profiles of apolipoproteins and apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias.
        Clin Chem. 1988; 34: B13
        • Albers J.J.
        • Adolphson J.L.
        Comparison of commercial kits for apoprotein A-I and apoprotein B with standardized apoprotein A-I and B radioimmunoassays performed at the Northwest Lipid Research Center.
        J Lipid Res. 1988; 29: 102
        • Albers J.J.
        • Adolphson J.L.
        • Hazzard W.R.
        Radioimmunoassay of human plasma Lp(a) lipoprotein.
        J Lipid Res. 1977; 18: 331
        • Albers J.J.
        • Bangdiwala S.I.
        • Tyroler H.A.
        • et al.
        Relationship of apolipoproteins and risk of coronary death: The Lipid Research Clinic′s program follow-up study.
        Circulation. 1984; 70: 268
        • Albers J.J.
        • Cabana V.G.
        • Hazzard W.R.
        Immunoassay of human plasma apolipoprotein B.
        Metabolism. 1975; 24: 1339
        • Albers J.J.
        • Hazzard W.R.
        Immunochemical quantification of human plasma Lp(a) lipoprotein.
        Lipids. 1974; 9: 15
        • Albers J.J.
        • Wahl P.W.
        • Cabana V.G.
        • et al.
        Quantification of apolipoprotein A-I of human plasma high density lipoprotein.
        Metabolism. 1976; 25: 633
        • Armstrong V.W.
        • Cremer P.
        • Eberle E.
        • et al.
        The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis.
        Atherosclerosis. 1986; 62: 249
        • Avogaro P.
        • BittoloBon G.
        • Cazzolato G.
        • et al.
        Are apolipoproteins better discriminators than lipids for atherosclerosis?.
        Lancet. 1979; 1: 901
        • Avogaro P.
        • Cazzolato G.
        • BittoloBon G.
        • et al.
        Values of apo-AI and apo-B in humans according to age and sex.
        Clin Chim Acta. 1979; 95: 311
        • Boerwinkle E.
        • Utermann G.
        Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism.
        Am J Hum Genet. 1988; 42: 104
        • Brunzell J.D.
        • Sniderman A.D.
        • Albers J.J.
        • et al.
        Apoproteins B and A-I and coronary artery disease in humans.
        Arteriosclerosis. 1984; 4: 79
        • Brunzell J.D.
        • Albers J.J.
        • Haas L.B.
        • et al.
        Prevalence of serum lipid abnormalities in chronic hemodialysis.
        Metabolism. 1977; 26: 903
        • Brunzell J.D.
        • Albers J.J.
        • Chait A.
        • et al.
        Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia.
        J Lipid Res. 1983; 24: 147
        • Dahlen G.H.
        Lipoprotein (a) in relation to atherosclerotic diseases.
        in: Naito H.K. Widhalm K. Recent aspects of diagnosis and treatment of lipoprotein disorders: Impact on Prevention of Atherosclerotic Diseases. Alan R Liss, New York1988: 27
        • DeBacker G.
        • Rosseneu M.
        • Deslypere J.P.
        Discriminative value of lipids and apoproteins in coronary heart disease.
        Atherosclerosis. 1982; 42: 197
        • Durrington P.N.
        • Ishola M.
        • Hunt L.
        • et al.
        Apolipoproteins(a), Al, and B and parental history in men with early onset ischaemic heart disease.
        Lancet. 1988; 1: 1070
      19. Expert Panel: Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults.
        Arch Intern Med. 1988; 148: 36
        • Fager G.
        • Wiklund O.
        • Olofsson S-O
        • et al.
        Multivariate analyses of serum apolipoproteins and risk factors in relation to acute myocardial infarction.
        Arteriosclerosis. 1981; 1: 273
        • Goodman D.S.
        The adult treatment panel guidelines.
        Clin Lab Med. 1989; 9: 17
        • Goldstein J.L.
        • Hazzard W.R.
        • Schrott H.G.
        • et al.
        Hyperlipidemia in coronary heart disease.
        J Clin Invest. 1973; 52: 1533
        • Grundy S.M.
        • Chait A.
        • Brunzell J.D.
        Familial Combined Hyperlipidemia Workshop.
        Arteriosclerosis. 1987; 7: 203
        • Ishikawa T.
        • Fidge N.
        • Thelle D.S.
        • et al.
        The Tromso heart study: Serum apolipoprotein A-I concentration in relation to future coronary heart disease.
        Eur J Clin Invest. 1978; 8: 179
        • Koltringer P.
        • Jurgens G.
        A dominant role of lipoprotein (a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis.
        Atherosclerosis. 1985; 58: 187
        • Kostner G.M.
        • Avogaro P.
        • Cazzolato G.
        • et al.
        Lipoprotein Lp(a) and the risk for myocardial infarction.
        Atherosclerosis. 1981; 38: 51

      27. Little RE, Wisjman E, Albers JJ, et al: Host and environmental effects on apolipoprotein B. Submitted for publication

        • Miller N.E.
        Associations of high density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis.
        Am Heart J. 1987; 113: 589
        • Murai A.
        • Miyahara T.
        • Fujimoto N.
        • et al.
        Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction.
        Atherosclerosis. 1986; 59: 199
        • Ordovas J.M.
        • Peterson J.P.
        • Santaniello P.
        • et al.
        Enzyme-linked immunosorbent assay for human plasma apolipoprotein B.
        J Lipid Res. 1987; 28: 1216
        • Rhoads G.G.
        • Dahlen G.
        • Berg K.
        • et al.
        Lp(a) lipoprotein as a risk factor for myocardial infarction.
        JAMA. 1986; 256: 2540
        • Riesen W.F.
        • Mordasini R.
        • Salzmann C.
        • et al.
        Apoproteins and lipids as discriminators of severity of coronary heart disease.
        Atherosclerosis. 1980; 37: 157
        • Salonen J.T.
        • Salonen R.
        • Penttila I.
        • et al.
        Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease.
        Am J Cardiol. 1985; 56: 226
        • Smith S.J.
        • Cooper G.R.
        • Henderson L.O.
        • et al.
        An international collaborative study on standardization of apolipoproteins A-I and B. Part I. Evaluation of a lyophilized candidate reference and calibration material.
        Clin Chem. 1987; 33: 2240
        • Sniderman A.
        • Shapiro S.
        • Marpole D.
        • et al.
        Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (B) lipoproteins].
        Proc Natl Acad Sci. 1980; 77: 604
        • Tollefson J.H.
        • Albers J.J.
        Isolation, characterization, and assay of plasma lipid transfer proteins.
        in: Albers J.J. Segrest J.P. Methods in Enzymology, Plasma Lipoproteins, Part B, Characterization, Cell Biology, and Metabolism. 129. Academic Press, Orlando1986: 797
        • Tyroler H.A.
        • Heiss G.
        • Schonfeld G.
        • et al.
        Apolipoprotein A-I, A-II and C-II in black and white residents of Evans County.
        Circulation. 1980; 62: 249
        • Vander Heiden G.L.
        • Barboriak J.L.
        • Sasse E.A.
        • et al.
        Correlation of the extent of coronary occlusion with apo B levels: Application of a new enzyme immunoassay technique for apo B.
        Atherosclerosis. 1984; 50: 29
        • Warnick G.R.
        • Mayfield C.
        • Albers J.J.
        • et al.
        Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia Type 3.
        Clin Chem. 1979; 25: 279
        • Whayne T.F.
        • Alaupovic P.
        • Curry M.D.
        • et al.
        Plasma apolipoprotein B and VLDL-, LDL-, and HDL-cholesterol as risk factors in the development of coronary artery disease in male patients examined by angiography.
        Atherosclerosis. 1981; 39: 411
        • Zenker G.
        • Koltringer P.
        • Bone G.
        • et al.
        Lipoprotein(a) as a strong indicator for cerebrovascular disease.
        Stroke. 1986; 17: 942

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30646-2

      Copyright

      © 1989 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX